|
#267 Small Hollow Nanodelivery Vehicles for Cancer Treatment
|
N43CO900077-000
|
$200,000
|
Baldwin, Richard
|
NANOCOMPOSIX INC:1166666
|
|
18F-Fluoroestradiol PET/CT guided fulvestrant therapy for patients with recurrent
|
1R21CA139814-01
|
$236,417
|
BENARD, FRANCOIS
|
BRITISH COLUMBIA CANCER AGENCY
|
|
1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
|
2R01CA101700-05A2
|
$357,353
|
GLICKSON, JERRY
|
UNIVERSITY OF PENNSYLVANIA
|
|
238th American Chemical Society National Meeting
|
1R13CA141800-01
|
$10,000
|
STURLA, SHANA
|
UNIVERSITY OF MINNESOTA TWIN CITIES
|
|
4'-Substituted nucleoside analogs as anticancer drugs
|
5R01CA124952-02
|
$456,229
|
SECRIST, JOHN
|
SOUTHERN RESEARCH INSTITUTE
|
|
4-Demethyl-4-cholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) Phase I Clinical Tr
|
5R43CA132257-02
|
$131,674
|
MORGAN, Lee
|
DEKK-TEC, INC.
|
|
5-Aminolevulinic acid-induced oxidative stress on cells by gold nanoparticles.
|
ZIA BC 011166
|
$113,246
|
Riesz, Peter
|
CCR (NCI)
|
|
8-Chloro-Adenosine for Treatment of CLL (IND 68,229)
|
1R21CA112907-01A2
|
$305,800
|
WIERDA, WILLIAM
|
UNIVERSITY OF TEXAS MD ANDERSON CAN CTR
|
|
A behavioral trial for parents of childhood cancer survivors with neurobehavioral
|
5R03CA130731-02
|
$83,000
|
Patel, Sunita
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
A comprehensive pharmacogenetic study of sorafenib in renal cell carcinoma patien
|
1R21CA139280-01
|
$205,920
|
INNOCENTI, FEDERICO
|
UNIVERSITY OF CHICAGO
|
|
A Drosophila Model for MEN2 and Sporadic MTCs
|
5R01CA084309-10
|
$236,780
|
Cagan, Ross
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
A Low-Dose Decitabine Strategy for Restoring Ovarian Cancer Sensitivity
|
5R21CA133877-02
|
$341,244
|
Matei, Daniela
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
A Mouse Model of TGFB1 and Tumor Immunosurveillance in Squamous Cell Cancer
|
5R01CA117957-04
|
$214,522
|
GLICK, ADAM
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
A nanoparticle prognosticator of chemotherapy outcomes
|
1R43CA141747-01
|
$139,513
|
LEBOVITZ, RUSSELL
|
MARVAL BIOSCIENCES, INC.
|
|
A Neoadjuvant Trial of Anastrazole and A Novel SRC Inhibitor, AZD0530, for LABC
|
1R21CA133884-01A1
|
$294,987
|
SLINGERLAND, JOYCE
|
UNIVERSITY OF MIAMI SCHOOL OF MEDICINE
|
|
A New Web 2.0 Platform for Analyzing Genomics Data with Application to the Study
|
1R41CA139639-01A1
|
$168,346
|
Myatt, Glenn
|
MYATT AND JOHNSON, INC.
|
|
A novel ellipticine analog as a therapeutic candidate for acute myeloid leukemia
|
1R43CA141915-01
|
$153,770
|
Agarwal, Mukesh
|
CLEVELAND LEUKEMIA THERAPEUTICS, LLC
|
|
A phase II study of IPI-504 in metastatic hormone refractory prostate cancer
|
5R21CA128352-02
|
$263,979
|
oh, william
|
DANA-FARBER CANCER INSTITUTE
|
|
A Phase II Trial of Riluzole in Patients with Advanced Melanoma
|
1R21CA139473-01A1
|
$343,200
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A Pilot Study of 5-FC and Genetically-Modified Neural Stem Cells to Treat Gliomas
|
1R21CA137639-01A1
|
$365,200
|
PORTNOW, JANA
|
CITY OF HOPE/BECKMAN RESEARCH INSTITUTE
|
|
A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
|
5R01CA051578-17
|
$236,153
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
|
A randomized phase II study of erlotinib with or without the anti-IGF-1R monoclon
|
5R21CA135595-02
|
$348,354
|
Camidge, Ross
|
UNIVERSITY OF COLORADO DENVER
|
|
Aberrant Crypt Foci as a Biomarker for Chemoprevention
|
5R01CA113681-04
|
$670,480
|
SINICROPE, FRANK
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S1
|
$114,606
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-34S3
|
$100,000
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
5P30CA016520-34
|
$7,326,647
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
ACOSOG Non Competing Renewal
|
5U10CA076001-13
|
$3,062,358
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
5R01CA085915-09
|
$311,259
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adoptive Immunotherapy for GBM During Hematopoietic Recovery from Temozolomide
|
1R01CA134844-01A2
|
$321,841
|
MITCHELL, DUANE
|
DUKE UNIVERSITY
|
|
Adrenocortical Cancer and Thyroid Carcinomas: Models with Unique Properties
|
ZIA BC 010626
|
$272,627
|
Fojo, Antonio
|
CCR (NCI)
|
|
Adult Brain Tumor Consortium (ABTC)
|
1U01CA137443-01
|
$2,000,000
|
GROSSMAN, STUART
|
JOHNS HOPKINS UNIVERSITY
|
|
Advanced Anatomic and Functional Response Assessment in Lung Cancer
|
5R01CA125143-03
|
$355,300
|
Schwartz, Lawrence
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
AID-mediated genetic instability in BCR-ABL1-transformed B cell lineage leukemia
|
1R01CA139032-01
|
$332,000
|
Muschen, Markus
|
CHILDREN'S HOSPITAL LOS ANGELES
|
|
AIDS and Cancer Specimen Resource Central Office and Data Coordinating Center
|
5U01CA096230-07
|
$739,770
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
AIDS Malignancy Clinical Trials Consortium
|
3U01CA121947-03S4
|
$3,605,692
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Alkyltransferase Inhibitors for Cancer Chemotherapy
|
5R01CA071976-14
|
$250,931
|
PEGG, ANTHONY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
|
5R01CA125153-04
|
$253,704
|
GANGJEE, ALEEM
|
DUQUESNE UNIVERSITY
|
|
Altered Arachidonic Acid Balance and Colon Cancer
|
5R01CA114635-04
|
$320,051
|
Rosenberg, Daniel
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
American Academy of Cancer Education Annuel Meetings - 2009, 2010, 2011
|
2R13CA126454-04
|
$39,500
|
VON GUNTEN, CHARLES
|
SAN DIEGO HOSPICE AND PALLIATIVE CARE
|
|
AML Stem Cell Heterogeneity: Implications for Gemtuzumab Ozogomicin-based Therapy
|
1K23CA137161-01A2
|
$121,236
|
Walter, Roland
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
An anti-CD74 MAb-drug conjugate for B-cell malignancies
|
5R44CA108083-03
|
$309,824
|
GOVINDAN, SERENGULAM
|
IMMUNOMEDICS, INC.
|
|
An Exploratory Study of Biologic and Pathophysiologic Efects of Radiation Therap
|
ZIA BC 010709
|
$97,616
|
Warren, Katherine
|
CCR (NCI)
|
|
Anaerobic Bacteria as Oncopathic Agents for Pancreatic Cancer
|
1R01CA130897-01A2
|
$351,713
|
Woo, Savio
|
MOUNT SINAI SCHOOL OF MEDICINE OF NYU
|
|
Analog Studies of 4-HPR and its Glucuronide
|
2R01CA049837-15A2
|
$352,401
|
CURLEY, ROBERT
|
OHIO STATE UNIVERSITY
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722001-003
|
$150,812
|
TURNER, GREGORY
|
MIDWEST RESEARCH INSTITUTE KANSAS CITY:1
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722002-003
|
$261,024
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE:1109097
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722003-003
|
$389,784
|
WANG, JENNIE
|
SRI INTERNATIONAL:1110101
|
|
Analysis of Patient Tumor Responses to Apo2L/TRAIL
|
5R01CA108888-04
|
$305,795
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Analysis of Redox Modulated Signaling Networks in Response to Ionizing Radiation
|
1R01CA136810-01A1
|
$314,223
|
Furdui, Cristina
|
WAKE FOREST UNIVERSITY HEALTH SCIENCES
|
|
Analysis of the Novel Kinase ROR2: A New Molecular Target in Renal Cell Carcinoma
|
5F31CA132543-02
|
$27,565
|
WRIGHT, TRICIA
|
UNIVERSITY OF NORTH CAROLINA CHAPEL HILL
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|